Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

This treatment has been approved for sale to the public.

Sponsor:

Information provided by (Responsible Party):

Boehringer Ingelheim

ClinicalTrials.gov Identifier:

NCT00097799

First received: November 30, 2004

Last updated: November 29, 2016

Last verified: October 2013

History of Changes

Purpose

This study was designed to provide early access to and evaluate the safety of TPV/r in PI-experienced patients with HIV-1 infection.

Condition	Intervention
HIV Infections	Drug: Tipranavir Drug: Ritonavir


Study Type:	Expanded Access What is Expanded Access?
Official Title:	An Open Label, Non-randomized Treatment Protocol of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Protease Inhibitor-experienced Patients With HIV-1 Infection (the Tipranavir Expanded Access Program)

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS

Drug Information available for: Ritonavir Tipranavir

U.S. FDA Resources

Further study details as provided by Boehringer Ingelheim:


Study Start Date:	December 2004
Primary Completion Date:	August 2005 (Final data collection date for primary outcome measure)

Intervention Details:

500 mg twice daily

200 mg twice daily

Eligibility


Ages Eligible for Study:	Child, Adult, Senior

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00097799

Show 115 Study Locations

Sponsors and Collaborators

Boehringer Ingelheim

Investigators


Study Chair:	Boehringer Ingelheim	Boehringer Ingelheim

More Information


Responsible Party:	Boehringer Ingelheim
ClinicalTrials.gov Identifier:	NCT00097799 History of Changes
Other Study ID Numbers:	1182.70
Study First Received:	November 30, 2004
Last Updated:	November 29, 2016

Additional relevant MeSH terms:


Infection Communicable Diseases HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Ritonavir	Tipranavir HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors

ClinicalTrials.gov processed this record on June 22, 2017

To Top